These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

709 related items for PubMed ID: 36414199

  • 1. Deciphering variable resistance to novel carbapenem-based β-lactamase inhibitor combinations in a multi-clonal outbreak caused by Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae resistant to ceftazidime/avibactam.
    Di Pilato V, Principe L, Andriani L, Aiezza N, Coppi M, Ricci S, Giani T, Luzzaro F, Rossolini GM.
    Clin Microbiol Infect; 2023 Apr; 29(4):537.e1-537.e8. PubMed ID: 36414199
    [Abstract] [Full Text] [Related]

  • 2. Susceptibility evaluation of novel beta-lactam/beta-lactamase inhibitor combinations against carbapenem-resistant Klebsiella pneumoniae from bloodstream infections in hospitalized patients in Brazil.
    Wilhelm CM, Antochevis LC, Magagnin CM, Arns B, Vieceli T, Pereira DC, Lutz L, de Souza ÂC, Dos Santos JN, Guerra RR, Medeiros GS, Santoro L, Falci DR, Rigatto MH, Barth AL, Martins AF, Zavascki AP.
    J Glob Antimicrob Resist; 2024 Sep; 38():247-251. PubMed ID: 38936472
    [Abstract] [Full Text] [Related]

  • 3. KPC-2 allelic variants in Klebsiella pneumoniae isolates resistant to ceftazidime-avibactam from Argentina: blaKPC-80, blaKPC-81, blaKPC-96 and blaKPC-97.
    Sanz MB, Pasteran F, de Mendieta JM, Brunetti F, Albornoz E, Rapoport M, Lucero C, Errecalde L, Nuñez MR, Monge R, Pennini M, Power P, Corso A, Gomez SA.
    Microbiol Spectr; 2024 Mar 05; 12(3):e0411123. PubMed ID: 38319084
    [Abstract] [Full Text] [Related]

  • 4. Antimicrobial activity of ceftazidime-avibactam against KPC-2-producing Enterobacterales: a cross-combination and dose-escalation titration study with relebactam and vaborbactam.
    Kang MS, Baek JY, Ko J-H, Cho SY, Lee KY, Lee YH, Yang J, Kim TY, Huh HJ, Lee NY, Huh K, Kang C-I, Chung DR, Peck KR.
    Microbiol Spectr; 2024 Jun 04; 12(6):e0034424. PubMed ID: 38687076
    [Abstract] [Full Text] [Related]

  • 5. In vivo selection of KPC-94 and KPC-95 in Klebsiella pneumoniae isolates from patients treated with ceftazidime/avibactam.
    Guzmán-Puche J, Pérez-Nadales E, Pérez-Vázquez M, Causse M, Gracia-Ahufinger I, Mendez-Natera A, Allalou-Ruiz Y, Elías C, Oteo-Iglesias J, Torre-Cisneros J, Martínez-Martínez L.
    Int J Antimicrob Agents; 2022 Feb 04; 59(2):106524. PubMed ID: 35038557
    [Abstract] [Full Text] [Related]

  • 6. Comparison of In Vitro Activity of Ceftazidime-Avibactam and Imipenem-Relebactam against Clinical Isolates of Pseudomonas aeruginosa.
    Wang L, Zhang X, Zhou X, Yang F, Guo Q, Wang M.
    Microbiol Spectr; 2023 Jun 15; 11(3):e0093223. PubMed ID: 37199669
    [Abstract] [Full Text] [Related]

  • 7. Dynamic evolution of imipenem/relebactam resistance in a KPC-producing Klebsiella pneumoniae from a single patient during ceftazidime/avibactam-based treatments.
    Gaibani P, Bovo F, Bussini L, Lazzarotto T, Amadesi S, Bartoletti M, Viale P, Ambretti S.
    J Antimicrob Chemother; 2022 May 29; 77(6):1570-1577. PubMed ID: 35373297
    [Abstract] [Full Text] [Related]

  • 8. In vitro activity of cefiderocol against ceftazidime-avibactam susceptible and resistant KPC-producing Enterobacterales: cross-resistance and synergistic effects.
    Bianco G, Boattini M, Comini S, Iannaccone M, Bondi A, Cavallo R, Costa C.
    Eur J Clin Microbiol Infect Dis; 2022 Jan 29; 41(1):63-70. PubMed ID: 34462816
    [Abstract] [Full Text] [Related]

  • 9. Functional features of KPC-109, a novel 270-loop KPC-3 mutant mediating resistance to avibactam-based β-lactamase inhibitor combinations and cefiderocol.
    Di Pilato V, Codda G, Niccolai C, Willison E, Wong JLC, Coppo E, Frankel G, Marchese A, Rossolini GM.
    Int J Antimicrob Agents; 2024 Jan 29; 63(1):107030. PubMed ID: 37931849
    [Abstract] [Full Text] [Related]

  • 10. Genomic characterization of a KPC-23-producing Klebsiella pneumoniae ST258 clinical isolate resistant to ceftazidime-avibactam.
    Galani I, Antoniadou A, Karaiskos I, Kontopoulou K, Giamarellou H, Souli M.
    Clin Microbiol Infect; 2019 Jun 29; 25(6):763.e5-763.e8. PubMed ID: 30928562
    [Abstract] [Full Text] [Related]

  • 11. Activity of ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam against carbapenemase-negative carbapenem-resistant Enterobacterales isolates from US hospitals.
    Castanheira M, Doyle TB, Deshpande LM, Mendes RE, Sader HS.
    Int J Antimicrob Agents; 2021 Nov 29; 58(5):106439. PubMed ID: 34547421
    [Abstract] [Full Text] [Related]

  • 12. A large-scale surveillance revealed that KPC variants mediated ceftazidime-avibactam resistance in clinically isolated Klebsiella pneumoniae.
    Qiao S, Xin S, Zhu Y, Zhao F, Wu H, Zhang J, Yao B, Yu Y, Fu Y, Jiang Y, Xie X, Zhang J.
    Microbiol Spectr; 2024 Aug 06; 12(8):e0025824. PubMed ID: 38958437
    [Abstract] [Full Text] [Related]

  • 13. In vitro mimicry of in vivo KPC mutations by ceftazidime-avibactam: phenotypes, mechanisms, genetic structure and kinetics of enzymatic hydrolysis.
    Shen S, Tang C, Yang W, Ding L, Han R, Shi Q, Guo Y, Yin D, Hu F.
    Emerg Microbes Infect; 2024 Dec 06; 13(1):2356146. PubMed ID: 38743401
    [Abstract] [Full Text] [Related]

  • 14. A novel KPC-166 in ceftazidime/avibactam resistant ST307 Klebsiella pneumoniae causing an outbreak in intensive care COVID Unit, Italy.
    Piazza A, Mattioni Marchetti V, Bielli A, Biffignandi GB, Piscopiello F, Giudici R, Tartaglione L, Merli M, Vismara C, Migliavacca R.
    J Microbiol Immunol Infect; 2024 Jun 06; 57(3):457-469. PubMed ID: 38584042
    [Abstract] [Full Text] [Related]

  • 15. Reversion of KPC-114 to KPC-2 in ceftazidime-avibactam- resistant/meropenem-susceptible Klebsiella pneumoniae ST11 is related to low mutation rates.
    Pariona JGM, Vásquez-Ponce F, Becerra J, Martins-Gonçalves T, Pariona EMM, Madueño FT, Esposito F, V de Lima A, Mello Sampaio JL, Galhardo RS, Lincopan N.
    Microbiol Spectr; 2024 Oct 03; 12(10):e0117324. PubMed ID: 39190636
    [Abstract] [Full Text] [Related]

  • 16. In Vitro Mechanisms of Resistance Development to Imipenem-Relebactam in KPC-Producing Klebsiella pneumoniae.
    Findlay J, Rens C, Poirel L, Nordmann P.
    Antimicrob Agents Chemother; 2022 Oct 18; 66(10):e0091822. PubMed ID: 36154170
    [Abstract] [Full Text] [Related]

  • 17. In vivo evolution to hypermucoviscosity and ceftazidime/avibactam resistance in a liver abscess caused by Klebsiella pneumoniae sequence type 512.
    Capitani V, Arcari G, Ambrosi C, Scribano D, Ceparano M, Polani R, De Francesco A, Raponi G, Ceccarelli G, Villari P, Palamara AT, Marzuillo C, Carattoli A.
    mSphere; 2024 Sep 25; 9(9):e0042324. PubMed ID: 39171923
    [Abstract] [Full Text] [Related]

  • 18. Ceftazidime-avibactam resistance and restoration of carbapenem susceptibility in KPC-producing Klebsiella pneumoniae infections: A case series.
    van Asten SAV, Boattini M, Kraakman MEM, Bianco G, Iannaccone M, Costa C, Cavallo R, Bernards AT.
    J Infect Chemother; 2021 May 25; 27(5):778-780. PubMed ID: 33558042
    [Abstract] [Full Text] [Related]

  • 19. Molecular Mechanisms Driving the In Vivo Development of KPC-71-Mediated Resistance to Ceftazidime-Avibactam during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections.
    Li X, Ke H, Wu W, Tu Y, Zhou H, Yu Y.
    mSphere; 2021 Dec 22; 6(6):e0085921. PubMed ID: 34935448
    [Abstract] [Full Text] [Related]

  • 20. Ceftazidime-Avibactam Resistance Associated with Increased blaKPC-3 Gene Copy Number Mediated by pKpQIL Plasmid Derivatives in Sequence Type 258 Klebsiella pneumoniae.
    Coppi M, Di Pilato V, Monaco F, Giani T, Conaldi PG, Rossolini GM.
    Antimicrob Agents Chemother; 2020 Mar 24; 64(4):. PubMed ID: 31964792
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.